Gain Therapeutics Plans To Initiate Phase 2 Rexaceract Trial In Q1 Next Year

Gain Therapeutics (Ticker: GANX) announced plans to initiate a Phase 2 clinical trial for Rexaceract in the first quarter of next year. This trial is a significant step in the company's development pipeline, aiming to advance its therapeutic offerings. Further details regarding the trial's design and objectives were not disclosed in the announcement.